Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease

Staging of brain pathology related to sporadic Parkinson’s disease

Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777

Epigenetic modifications and human disease

Portela, A., & Esteller, M. (2010) · Nature Biotechnology · doi:10.1038/nbt.1685 · Cited by 2,938

The prevalence of Parkinson's disease: a systematic review and meta-analysis

Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014) · Movement Disorders · doi:10.1002/mds.25945 · Cited by 2,188

Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease

International Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895

MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE

Schapira, A. H. V., Cooper, J. A. D., Dexter, D. T., Jenner, P. G., Clark, J. B., & MARSDEN, C. D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92366-0 · Cited by 1,757

An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells

Mezrich, J. D., Fechner, J. H., Zhang, X., Johnson, B. P., Burlingham, W. J., & Bradfield, C. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903670 · Cited by 1,674

Pesticides and human chronic diseases: Evidences, mechanisms, and perspectives

Mostafalou, S., & Abdollahi, M. R. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.01.025 · Cited by 1,333

Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid

Beal, M. F., Kowall, N. W., Ellison, D. W., Mazurek, M. F., Swartz, K. J., & Martin, J. B. (1986) · Nature · doi:10.1038/321168a0 · Cited by 1,287

Immune system to brain signaling: Neuropsychopharmacological implications

Capuron, L., & Miller, A. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.014 · Cited by 1,195

100 years of Lewy pathology

Goedert, M., Spillantini, M. G., Del Tredici, K., & Braak, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.242 · Cited by 1,190

Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?

Reeve, A. K., Simcox, E. M., & Turnbull, D. M. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.01.004 · Cited by 1,013

The Brain Metabolite Kynurenic Acid Inhibits α7 Nicotinic Receptor Activity and Increases Non-α7 Nicotinic Receptor Expression: Physiopathological Implications

Hilmas, C. J., Pereira, E. F. R., Alkondon, M., Rassoulpour, A., Schwarcz, R. M., & Albuquerque, E. X. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07463.2001 · Cited by 875

An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid

Perkins, M. N., & Stone, T. W. (1982) · Brain Research · doi:10.1016/0006-8993(82)91048-4 · Cited by 849

Endogenous kynurenines as targets for drug discovery and development

Stone, T. W., & Darlington, L. G. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd870 · Cited by 768

Blood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism

Fukui, S., Schwarcz, R. M., Rapoport, S. I., Takada, Y., & Smith, Q. R. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb03460.x · Cited by 765

Tryptophan and the immune response

Moffett, J., & Namboodiri, M. (2003) · Immunology and Cell Biology · doi:10.1046/j.1440-1711.2003.t01-1-01177.x · Cited by 765

Innate immunity: the missing link in neuroprotection and neurodegeneration?

Nguyen, M. D., Julien, J., & Rivest, S. (2002) · Nature reviews. Neuroscience · doi:10.1038/nrn752 · Cited by 710

Aryl hydrocarbon receptor control of a disease tolerance defence pathway

Bessede, A., Gargaro, M., Pallotta, M. T., Matino, D., Servillo, G., Brunacci, C., Bicciato, S., Mazza, E. M. C., Macchiarulo, A., Vacca, C., et al. (2014) · Nature · doi:10.1038/nature13323 · Cited by 693

Mitochondrial dysfunction in Parkinson's disease

Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688

Metabotropic glutamate receptors: From the workbench to the bedside

Nicoletti, F., Bockaert, J., Collingridge, G. L., Conn, P. J., Ferraguti, F., Schoepp, D. D., Wroblewski, J. T., & Pin, J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.10.022 · Cited by 680

Kynurenic Acid Is a Potent Endogenous Aryl Hydrocarbon Receptor Ligand that Synergistically Induces Interleukin-6 in the Presence of Inflammatory Signaling

DiNatale, B. C., Murray, I. A., Schroeder, J. C., Flaveny, C. A., Lahoti, T. S., Laurenzana, E. M., Omiecinski, C. J., & Perdew, G. H. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq024 · Cited by 651

Kynurenine Pathway Metabolites in Humans: Disease and Healthy States

Chen, Y., & Guillemin, G. J. (2009) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s2097 · Cited by 642

Kynurenines in the CNS: recent advances and new questions

Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3793 · Cited by 641

Quinolinic acid, the inescapable neurotoxin

Guillemin, G. J. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08485.x · Cited by 595

Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: Evidence for an immune-modulated glutamatergic neurotransmission?

Steiner, J., Walter, M., Gos, T., Guillemin, G. J., Bernstein, H.-G., Sarnyai, Z., Mawrin, C., Brisch, R., Bielau, H., zu Schwabedissen, L., et al. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-94 · Cited by 568

Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection

Guillemin, G. J., Kerr, S. J., Smythe, G. A., Smith, D. G., Kapoor, V., Armati, P. J., Croitoru‐Lamoury, J., & Brew, B. J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00498.x · Cited by 541

Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database

Lill, C. M., Roehr, J. T., McQueen, M. B., Kavvoura, F. K., Bagade, S., Schjeide, B. M., Schjeide, L. M., Meissner, E., Zauft, U., Allen, N. C., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002548 · Cited by 541

Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease

Berg, D., Postuma, R. B., Bloem, B. R., Chan, P., Dubois, B., Gasser, T., Goetz, C. G., Halliday, G. M., Hardy, J., Lang, A. E., et al. (2014) · Movement Disorders · doi:10.1002/mds.25844 · Cited by 502

Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons

Guillemin, G. J., Smythe, G., Takikawa, O., & Brew, B. J. (2005) · Glia · doi:10.1002/glia.20090 · Cited by 497 · cited 5×

Astrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease

Cabezas, R., Ávila, M. F., González, J., El-Bachá, R. D. S., Báez-Jurado, E., García‐Segura, L. M., Jurado-Coronel, J. C., Capani, F., Cardona‐Gómez, G. P., & Barreto, G. E. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00211 · Cited by 481

Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates

Collier, T. J., Kanaan, N. M., & Kordower, J. H. (2011) · Nature reviews. Neuroscience · doi:10.1038/nrn3039 · Cited by 469

Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration

Jang, H., Boltz, D. A., Sturm-Ramirez, K. M., Shepherd, K. R., Jiao, Y., Webster, R. G., & Smeyne, R. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900096106 · Cited by 468

Parkinson’s disease dementia: a neural networks perspective

Gratwicke, J., Jahanshahi, M., & Foltynie, T. (2015) · Brain · doi:10.1093/brain/awv104 · Cited by 459

Cutting Edge: Induced Indoleamine 2,3 Dioxygenase Expression in Dendritic Cell Subsets Suppresses T Cell Clonal Expansion

Mellor, A. L., Baban, B., Chandler, P., Marshall, B., Jhaver, K. G., Hansen, A. M., Koni, P. A., Iwashima, M., & Munn, D. H. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.4.1652 · Cited by 457

Glia: Initiators and progressors of pathology in Parkinson's disease

Halliday, G. M., & Stevens, C. H. (2011) · Movement Disorders · doi:10.1002/mds.23455 · Cited by 436

Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid

Foster, A. C., Vezzani, A., French, E. D., & Schwarcz, R. M. (1984) · Neuroscience Letters · doi:10.1016/0304-3940(84)90050-8 · Cited by 435

NMDA Receptor Blockade by Ketamine Abrogates Lipopolysaccharide-Induced Depressive-Like Behavior in C57BL/6J Mice

Walker, A. K., Budac, D. P., Bisulco, S., Lee, A. W., Smith, R. A., Beenders, B., Kelley, K. W., & Dantzer, R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.71 · Cited by 432

Pesticides exposure as etiological factors of Parkinson's disease and other neurodegenerative diseases—A mechanistic approach

Baltazar, M. T., Dinis‐Oliveira, R. J., Bastos, M. D. L., Tsatsakis, A. M., Duarte, J. A., & Carvalho, F. D. (2014) · Toxicology Letters · doi:10.1016/j.toxlet.2014.01.039 · Cited by 410

Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives

Schapira, A. H. V., Olanow, C. W., Greenamyre, J. T., & Bézard, E. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61010-2 · Cited by 399

Quinolinic acid: an endogenous neurotoxin with multiple targets

Lugo-Huitrón, R., Ugalde Muñiz, P., Pineda, B., Pedraza-Chaverrí, J., Ríos, C., & Pérez-de la Cruz, V. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/104024 · Cited by 394

Editorial (Thematic Issue: Mitochondrial Biogenesis: Pharmacological Approaches)

Valero, T. (2014) · Current Pharmaceutical Design · doi:10.2174/138161282035140911142118 · Cited by 370

On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress

Lugo-Huitrón, R., Blanco-Ayala, T., Ugalde-Muñiz, P., Carrillo-Mora, P., Pedraza-Chaverrí, J., Silva-Adaya, D., Maldonado, P. D., Torres, I., Pinzón, E., Ortiz-Islas, E., et al. (2011) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2011.07.002 · Cited by 346

Connecting inflammation with glutamate agonism in suicidality

Erhardt, S., Lim, C. K., Linderholm, K. R., Janelidze, S., Lindqvist, D., Samuelsson, M., Lundberg, K., Postolache, T. T., Träskman-Bendz, L., Guillemin, G. J., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.248 · Cited by 345

Indoleamine 2,3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus

Guillemin, G. J., Brew, B. J., Noonan, C. E., Takikawa, O., & Cullen, K. M. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2005.00655.x · Cited by 338

The Role of Inflammatory and Oxidative Stress Mechanisms in the Pathogenesis of Parkinson’s Disease: Focus on Astrocytes

Niranjan, R. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8483-x · Cited by 338

Characterization of the Kynurenine Pathway in Human Neurons

Guillemin, G. J., Cullen, K. M., Lim, C. K., Smythe, G. A., Garner, B., Kapoor, V., Takikawa, O., & Brew, B. J. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.4101-07.2007 · Cited by 331

Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes

Tavares, R. G., Tasca, C. I., Santos, C. E. S., Alves, L. B., Porciúncula, L. O., Emanuelli, T., & Souza, D. O. (2002) · Neurochemistry International · doi:10.1016/s0197-0186(01)00133-4 · Cited by 320

Kynurenine pathway abnormalities in Parkinson's disease

Ogawa, T., Matson, W. R., Beal, M. F., Myers, R. H., Bird, E. D., Milbury, P. E., & Saso, S. (1992) · Neurology · doi:10.1212/wnl.42.9.1702 · Cited by 317

Kynurenine Pathway Measurements in Huntington's Disease Striatum: Evidence for Reduced Formation of Kynurenic Acid

Beal, M. F., Matson, W. R., Swartz, K. J., Gamache, P. H., & Bird, E. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb03143.x · Cited by 312

A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality

Bay-Richter, C., Linderholm, K. R., Lim, C. K., Samuelsson, M., Träskman-Bendz, L., Guillemin, G. J., Erhardt, S., & Brundin, L. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.07.012 · Cited by 304

Viral parkinsonism

Jang, H., Boltz, D. A., Webster, R. G., & Smeyne, R. J. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.08.001 · Cited by 298

Inflammation, Glutamate, and Glia in Depression:A Literature Review

McNally, L., Bhagwagar, Z., & Hannestad, J. (2008) · CNS Spectrums · doi:10.1017/s1092852900016734 · Cited by 289

Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis.

Guridi, J., Herrero, M., Luquin, M., Guillén, J., Ruberg, M., Laguna, J., Vila, M., Javoy-Agid, F., Agid, Y., Hirsch, E., et al. (1996) · Brain : a journal of neurology · doi:10.1093/brain/119.5.1717 · Cited by 287

Microglial Reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) Induced Parkinson's Disease Mice Model

Członkowska, A., Kohutnicka, M., Kurkowska‐Jastrzębska, I., & Członkowski, A. (1996) · Neurodegeneration · doi:10.1006/neur.1996.0020 · Cited by 279

Quinolinic acid is a potent lipid peroxidant in rat brain homogenates

Rı́os, C., & Santamarı́a, A. (1991) · Neurochemical Research · doi:10.1007/bf00966592 · Cited by 272

Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder

Savitz, J., Drevets, W. C., Smith, C. M., Victor, T. A., Wurfel, B. E., Bellgowan, P. S., Bodurka, J., Teague, T. K., & Dantzer, R. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.194 · Cited by 272

Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states

Lévy, R., Hazrati, L., Herrero, M. T., Vila, M., Hassani, O.-K., Mouroux, M., Ruberg, M., Asensi, H., Agid, Y., Féger, J., et al. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00409-5 · Cited by 270

Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics

Zecca, L., Zucca, F. A., Wilms, H., & Sulzer, D. L. (2003) · Trends in Neurosciences · doi:10.1016/j.tins.2003.08.009 · Cited by 265

The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons

Rahman, A., Ting, K., Cullen, K. M., Braidy, N., Brew, B. J., & Guillemin, G. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006344 · Cited by 257

IDO and tolerance to tumors

Munn, D. H., & Mellor, A. L. (2003) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2003.11.003 · Cited by 257

Glutamate Receptors as Therapeutic Targets for Parkinsons Disease

Johnson, K. A., Conn, P. J., & Niswender, C. M. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824606 · Cited by 251

Gene expression analysis in N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R‐apomorphine

Grünblatt, E., Mandel, S. A., Maor, G., & Youdim, M. B. H. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00397.x · Cited by 246

Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease

Allen Reish, H. E., & Standaert, D. G. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-140491 · Cited by 244

Metabolic features of the cell danger response

Naviaux, R. K. (2013) · Mitochondrion · doi:10.1016/j.mito.2013.08.006 · Cited by 243

Differential vulnerability of central neurons of the rat to quinolinic acid

Schwarcz, R., & Köhler, C. (1983) · Neuroscience Letters · doi:10.1016/0304-3940(83)90115-5 · Cited by 239

Organelle-specific initiation of cell death

Galluzzi, L., Bravo-San Pedro, J. M., & Kroemer, G. (2014) · Nature Cell Biology · doi:10.1038/ncb3005 · Cited by 239

Non-Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Inflammatory Cytokines in Serum

Lindqvist, D., Kaufman, E., Brundin, L., Hall, S., Surova, Y., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047387 · Cited by 236

Neopterin production, tryptophan degradation, and mental depression—What is the link?

Widner, B., Laich, A., Sperner‐Unterweger, B., Ledochowski, M., & Fuchs, D. (2002) · Brain Behavior and Immunity · doi:10.1016/s0889-1591(02)00006-5 · Cited by 235

Mechanism for Quinolinic Acid Cytotoxicity in Human Astrocytes and Neurons

Braidy, N., Grant, R., Adams, S., Brew, B., & Guillemin, G. (2009) · Neurotoxicity research · doi:10.1007/s12640-009-9051-z · Cited by 234

Chapter 36: Astrocytes and Parkinson's disease

Forno, L. S., DeLanney, L. E., Irwin, I., Monte, D. A. D., & Langston, J. W. (1992) · Progress in brain research · doi:10.1016/s0079-6123(08)61770-7 · Cited by 230

Expression of The Kynurenine Pathway Enzymes in Human Microglia and Macrophages

Guillemin, G. J., Smith, D. G., Smythe, G. A., Armati, P. J., & Brew, G. J. (2003) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4615-0135-0_12 · Cited by 229

Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl

Behan, W. M. H., McDonald, M., Darlington, L. G., & Stone, T. W. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702940 · Cited by 225

NMDA receptors and ligands in the vertebrate CNS

Stone, T. W. (1988) · Progress in Neurobiology · doi:10.1016/0301-0082(88)90027-5 · Cited by 223

Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex

Beal, M. F., Matson, W. R., Storey, E., Milbury, P. E., Ryan, E. A., Ogawa, T., & Bird, E. D. (1992) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(92)90191-m · Cited by 220

Nigral pathology and parkinsonian signs in elders without Parkinson disease

Buchman, A. S., Shulman, J. M., Nag, S., Leurgans, S. E., Arnold, S. E., Morris, M. C., Schneider, J. A., & Bennett, D. A. (2011) · Annals of Neurology · doi:10.1002/ana.22588 · Cited by 220

The Physiological Action of Picolinic Acid in the Human Brain

Grant, R., Coggan, S. E., & Smythe, G. A. (2009) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s2469 · Cited by 219

Pharmacology and regional variations of quinolinic acid-evoked excitations in the rat central nervous system.

Perkins, M. N., & Stone, T. W. (1983) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21648-2 · Cited by 215

Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease

Guillemin, G. J., & Brew, B. J. (2002) · Redox Report · doi:10.1179/135100002125000550 · Cited by 214

3-Hydroxykynurenine and 3-Hydroxyanthranilic Acid Generate Hydrogen Peroxide and Promote α-Crystallin Cross-Linking by Metal Ion Reduction

Goldstein, L. E., Leopold, M. C., Huang, X., Atwood, C., Saunders, A. J., Hartshorn, M. A., Lim, J. T., Faget, K. Y., Muffat, J., Scarpa, R. C., et al. (2000) · Biochemistry · doi:10.1021/bi992997s · Cited by 212

Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection

Stone, T. W. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01451-6 · Cited by 211

Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure

Barcia, C., Sánchez-Bahíllo, A., Fernández‐Villalba, E., Bautista‐Hernández, V., Poza, M., Fernández-Barreiro, A., Hirsch, É. C., & Herrero, M. T. (2004) · Glia · doi:10.1002/glia.20015 · Cited by 206

IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease

Barcia, C., Ros, C. M., Annese, V, Gómez, A., Ros-Bernal, F., Aguado-Llera, D., Martínez-Pagán, M. E., de Pablos, V, Fernandez-Villalba, E., & Herrero, M. T. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.17 · Cited by 203

Parkinson's disease: Evidence for environmental risk factors

Kieburtz, K. D., & Wunderle, K. B. (2012) · Movement Disorders · doi:10.1002/mds.25150 · Cited by 199

Characterisation of the Expression of NMDA Receptors in Human Astrocytes

Lee, M.-C., Ting, K. K., Adams, S., Brew, B. J., Chung, R. S., & Guillemin, G. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014123 · Cited by 195

On the excitotoxic properties of quinolinic acid, 2,3-piperidine dicarboxylic acids and structurally related compounds

Foster, A. C. (1983) · Neuropharmacology · doi:10.1016/0028-3908(83)90221-6 · Cited by 194

Persistent S-Nitrosation of Complex I and Other Mitochondrial Membrane Proteins by S-Nitrosothiols but Not Nitric Oxide or Peroxynitrite

Dahm, C. C., Moore, K., & Murphy, M. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512203200 · Cited by 194

The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes

Lisi, L., Navarra, P., Feinstein, D., & Russo, C. D. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-1 · Cited by 194

Quinolinic Acid, an Endogenous Molecule Combining Excitotoxicity, Oxidative Stress and Other Toxic Mechanisms

de la Cruz, V. P., Carrillo-Mora, P. U., & Santamarı́a, A. (2012) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s8158 · Cited by 193

Alpha-synuclein spreading in Parkinson’s disease

Recasens, A., & Dehay, B. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00159 · Cited by 192

Pathology associated with sporadic Parkinson’s disease — where does it end?

Braak, H., Müller, C. M., Rüb, U., Ackermann, H., Bratzke, H., de Vos, R. A. I., & Tredici, K. D. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_15 · Cited by 182

3‐Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum

Guidetti, P., & Schwarcz, R. M. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00806.x · Cited by 180

Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes

Guillemin, G. J., Croitoru‐Lamoury, J., Dormont, D., Armati, P. J., & Brew, B. J. (2003) · Glia · doi:10.1002/glia.10175 · Cited by 176

Inflammation in Parkinson’s disease: role of glucocorticoids

Herrero, M.-T., Estrada, C., Maatouk, L., & Vyas, S. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00032 · Cited by 175 · cited 1×

The sour side of neurodegenerative disorders: the effects of protein glycation

Miranda, H. V., & Outeiro, T. F. (2009) · The Journal of Pathology · doi:10.1002/path.2682 · Cited by 172

Effect of Wild-type or Mutant Parkin on Oxidative Damage, Nitric Oxide, Antioxidant Defenses, and the Proteasome

Hyun, D.-H., Lee, M., Hattori, N., Kubo, S.-I., Mizuno, Y., Halliwell, B., & Jenner, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200666200 · Cited by 172

Increased neopterin production and tryptophan degradation in advanced Parkinson's disease.

Widner, B., Leblhuber, F., & Fuchs, D. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200014 · Cited by 171

3‐hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis

LeWitt, P. A., Li, J., Lü, M., Beach, T. G., Adler, C. H., & Guo, L. (2013) · Movement Disorders · doi:10.1002/mds.25555 · Cited by 171

Kynurenic Acid Triggers Firm Arrest of Leukocytes to Vascular Endothelium under Flow Conditions

Barth, M. C., Ahluwalia, N., Anderson, T. J. T., Hardy, G. J., Sinha, S., Alvarez-Cardona, J. A., Pruitt, I. E., Rhee, E. P., Colvin, R. A., & Gerszten, R. E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.024042 · Cited by 170

The role of inflammation in sporadic and familial Parkinson’s disease

Deleidi, M., & Gasser, T. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1352-y · Cited by 169

Downregulated Kynurenine 3-Monooxygenase Gene Expression and Enzyme Activity in Schizophrenia and Genetic Association With Schizophrenia Endophenotypes

Wonodi, I., Stine, O. C., Sathyasaikumar, K. V., Roberts, R. C., Mitchell, B. D., Hong, L. E., Kajii, Y., Thaker, G. K., & Schwarcz, R. M. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.71 · Cited by 168

Oxidative Stress and Microglial Cells in Parkinson's Disease

Peterson, L. J., & Flood, P. M. (2012) · Mediators of Inflammation · doi:10.1155/2012/401264 · Cited by 167

Noncanonical NF-κB signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) induction and immune regulation

Tas, S. W., Vervoordeldonk, M. J., Hajji, N., Schuitemaker, J. H. N., van der Sluijs, K., May, M. J., Ghosh, S., Kapsenberg, M. L., Tak, P. P., & de Jong, E. C. (2007) · Blood · doi:10.1182/blood-2006-11-056010 · Cited by 167

Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease

Ting, K. K., Brew, B. J., & Guillemin, G. J. (2009) · Journal of Neuroinflammation · doi:10.1186/1742-2094-6-36 · Cited by 166

Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired blood–brain barrier integrity

Steiner, J. H., Bogerts, B., Sarnyai, Z., Walter, M., Gos, T., Bernstein, H., & Myint, A.-M. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.583941 · Cited by 162

Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line

Eastman, C. L., & Guilarte, T. R. (1989) · Brain Research · doi:10.1016/0006-8993(89)90216-3 · Cited by 161

The quinolinic acid model of Huntington's disease: Locomotor abnormalities

Sanberg, P. R., Calderon, S. F., Giòrdano, M., et al. (1989) · Experimental Neurology · doi:10.1016/0014-4886(89)90170-2 · Cited by 160

LC3 binds externalized cardiolipin on injured mitochondria to signal mitophagy in neurons

Chu, C. T., Bayır, H., & Kagan, V. E. (2013) · Autophagy · doi:10.4161/auto.27191 · Cited by 159

NAD+metabolism and oxidative stress: the golden nucleotide on a crown of thorns

Massudi, H., Grant, R., Guillemin, G. J., & Braidy, N. (2012) · Redox Report · doi:10.1179/1351000212y.0000000001 · Cited by 158

Consequences of Nigrostriatal Denervation on the Functioning of the Basal Ganglia in Human and Nonhuman Primates: AnIn SituHybridization Study of Cytochrome Oxidase Subunit I mRNA

Vila, M., Lévy, R., Herrero, M. T., Ruberg, M., Faucheux, B. A., Obeso, J. A., Agid, Y., & Hirsch, É. C. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-02-00765.1997 · Cited by 158

The Kynurenine Pathway in Brain Tumor Pathogenesis

Adams, S., Braidy, N., Bessesde, A., Brew, B. J., Grant, R., Teo, C., & Guillemin, G. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0549 · Cited by 157

Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson’s disease

Tufi, R., Gandhi, S., de Castro, I. P., Lehmann, S., Angelova, P. R., Dinsdale, D. D., Deas, E., Plun‐Favreau, H., Nicotera, P., Abramov, A. Y., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2901 · Cited by 156

Quinolinic acid induces oxidative stress in rat brain synaptosomes

Santamarı́a, A., Galván‐Arzate, S., Lisý, V., Ali, S. F., Duhart, H. M., Osorio‐Rico, L., Rı́os, C., & Sut'astný, F. (2001) · Neuroreport · doi:10.1097/00001756-200103260-00049 · Cited by 152

ROCK/Cdc42-mediated microglial motility and gliapse formation lead to phagocytosis of degenerating dopaminergic neurons in vivo

Barcia, C., Ros, C. M., Annese, V., Carrillo-de Sauvage, M. A., Ros-Bernal, F., Gómez, A., Yuste, J. E., Campuzano, C. M., de Pablos, V., Fernandez-Villalba, E., et al. (2012) · Scientific Reports · doi:10.1038/srep00809 · Cited by 150

Involvement of the Kynurenine Pathway in Human Glioma Pathophysiology

Adams, S., Teo, C., McDonald, K. L., Zinger, A., Bustamante, S., Lim, C. K., Sundaram, G., Braidy, N., Brew, B. J., & Guillemin, G. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112945 · Cited by 149

Quinolinic Acid Production by Macrophages Stimulated with IFN-γ, TNF-α, and IFN-α

PEMBERTON, L. A., KERR, S. J., SMYTHE, G., & BREW, B. J. (1997) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1997.17.589 · Cited by 149

Oxidative and nitrative alpha‐synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies

Schildknecht, S., Gerding, H. R., Karreman, C., Drescher, M., Lashuel, H. A., Outeiro, T. F., Di Monte, D. A., & Leist, M. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12226 · Cited by 148

THE ENDOGENEOUS AGONIST QUINOLINIC ACID AND THE NON ENDOGENOUS HOMOQUINOLINIC ACID DISCRIMINATE BETWEEN NMDAR2 RECEPTOR SUBUNITS

de Carvalho, L. P., Bochet, P., & Rossier, J. (1996) · Neurochemistry International · doi:10.1016/0197-0186(95)00091-7 · Cited by 145

Dynamic O-GlcNAcylation and its roles in the cellular stress response and homeostasis

Groves, J. A., Lee, A., Yildirir, G., & Zachara, N. E. (2013) · Cell Stress and Chaperones · doi:10.1007/s12192-013-0426-y · Cited by 143

Acetyl-l-carnitine and α-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy

Zaitone, S. A., Abo–Elmatty, D. M., & Shaalan, A. A. M. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.002 · Cited by 141

The kynurenine pathway and inflammation in amyotrophic lateral sclerosis

Chen, Y., Stankovic, R., Cullen, K. M., Meininger, V., Garner, B., Coggan, S., Grant, R., Brew, B. J., & Guillemin, G. J. (2010) · Neurotoxicity Research · doi:10.1007/s12640-009-9129-7 · Cited by 141

Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid

Miranda, A., Boegman, R. J., Beninger, R. J., & Jhamandas, K. H. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00655-0 · Cited by 139

Dopamine Receptor D3 Expressed on CD4+ T Cells Favors Neurodegeneration of Dopaminergic Neurons during Parkinson’s Disease

Velozo, H. G., Contreras, F., Prado, C. E., Elgueta, D., Demane, D. F., Bernales, S., & Pacheco, R. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203121 · Cited by 138

Identification of Cinnabarinic Acid as a Novel Endogenous Aryl Hydrocarbon Receptor Ligand That Drives IL-22 Production

Lowe, M. M., Mold, J. E., Kanwar, B., Huang, Y., Louie, A., Pollastri, M. P., Wang, C., Patel, G., Franks, D. G., Schlezinger, J. J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087877 · Cited by 136

Involvement of quinolinic acid in aids dementia complex

Guillemin, G. J., Kerr, S. J., & Brew, B. J. (2005) · Neurotoxicity Research · doi:10.1007/bf03033781 · Cited by 135

Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex

Guillemin, G. J., Wang, L. H.-C., & Brew, B. J. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-16 · Cited by 135

TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson’s disease via CNTF

Nam, J. H., Park, E. S., Won, S.-Y., Lee, Y. A., Kim, K. I., Jeong, J. Y., Baek, J. Y., Cho, E. J., Jin, M., Chung, Y. C., et al. (2015) · Brain · doi:10.1093/brain/awv297 · Cited by 134

Structural basis of kynurenine 3-monooxygenase inhibition

Amaral, M., Levy, C., Heyes, D. J., Lafite, P., Outeiro, T. F., Giorgini, F., Leys, D., & Scrutton, N. S. (2013) · Nature · doi:10.1038/nature12039 · Cited by 134

Handbook of Neurotoxicity

Kostrzewa, R. M. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4 · Cited by 134

Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases

Jauch, D., Urbańska, E. M., Guidetti, P., Bird, E. D., Vonsattel, J., Whetsell, W. O., & Schwarcz, R. M. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)00280-2 · Cited by 127

MK-801, an receptor antagonist, blocks quinolinic acid-induced lipid peroxidation in rat corpus striatum

Santamarı́a, A., & Rı́os, C. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90796-n · Cited by 126

Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism

Graham, W. C., Robertson, R. G., Sambrook, M. A., & Crossman, A. R. (1990) · Life Sciences · doi:10.1016/0024-3205(90)90376-3 · Cited by 126

TNF-α regulates miRNA targeting mitochondrial complex-I and induces cell death in dopaminergic cells

Prajapati, P., Sripada, L., Singh, K., Bhatelia, K., Singh, R. K., & Singh, R. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.11.019 · Cited by 124

Imbalanced Kynurenine Pathway in Schizophrenia

Kegel, M. E., Bhat, M., Skogh, E., Samuelsson, M., Lundberg, K., Dahl, M., Sellgren, C. M., Schwieler, L., Engberg, G., Schuppe‐Koistinen, I., et al. (2014) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s16800 · Cited by 122

Kinases and kinase signaling pathways: Potential therapeutic targets in Parkinson's disease

Wang, G., Pan, J., & Chen, S. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.06.003 · Cited by 117

Quinolinic acid inhibits glutamate uptake into synaptic vesicles from rat brain

Tavares, R. G., Tasca, C. I., dos Santos, C. E. S., Wajner, M., Souza, D. O., & Dutra‐Filho, C. S. (2000) · Neuroreport · doi:10.1097/00001756-200002070-00005 · Cited by 117

Kynurenine Pathway Enzymes in Brain: Responses to Ischemic Brain Injury Versus Systemic Immune Activation

Saito, K., Nowak, T. S., Suyama, K., Quearry, B. J., Saito, M., Crowley, J. S., Markey, S. P., & Heyes, M. P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb07443.x · Cited by 116

Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat

Danielle G Smith, G. J. G. (2001) · Journal of NeuroVirology · doi:10.1080/135502801300069692 · Cited by 116

Kynurenine metabolism in multiple sclerosis

Hartai, Z., Klivènyi, P., Janáky, T., Penke, B., Dux, L., & Vécsei, L. (2005) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2005.00442.x · Cited by 115

The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine

Eastman, C. L., & Guilarte, T. R. (1990) · Neurochemical Research · doi:10.1007/bf01101711 · Cited by 113

The pharmacological manipulation of glutamate receptors and neuroprotection

Stone, T. W., & Addae, J. I. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01851-4 · Cited by 113

Transplanted adult neural progenitor cells survive, differentiate and reduce motor function impairment in a rodent model of Huntington's disease

Vazey, E. M., Chen, K. C., Hughes, S. M., & Connor, B. J. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.01.034 · Cited by 112

Kynurenine pathway metabolism in human blood–brain–barrier cells: implications for immune tolerance & neurotoxicity

Owe‐Young, R., Webster, N. L., Mukhtār, M., Pomerantz, R. J., Smythe, G. A., Walker, D. W., Armati, P. J., Crowe, S. M., & Brew, B. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05241.x · Cited by 112

α-Synuclein Vaccination Prevents the Accumulation of Parkinson Disease-Like Pathologic Inclusions in Striatum in Association With Regulatory T Cell Recruitment in a Rat Model

Sánchez-Guajardo, V., Annibali, A., Jensen, P. H., & Romero‐Ramos, M. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31829768d2 · Cited by 110

Neuroprotective effects of naturally occurring polyphenols on quinolinic acid‐induced excitotoxicity in human neurons

Braidy, N., Grant, R., Adams, S., & Guillemin, G. J. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07487.x · Cited by 110

Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability

Pieper, H. C., Evert, B. O., Kaut, O., Riederer, P. F., Waha, A., & Wüllner, U. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.09.010 · Cited by 108

Similarities and differences in the neuronal death processes activated by 3OH‐kynurenine and quinolinic acid

Chiarugi, A., Meli, E., & Moroni, F. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00335.x · Cited by 107

In vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum

Santamarı́a, A., Jiménez-Capdeville, M. E., Camacho‐Morales, A., Rodrı́guez-Martı́nez, E., Flores, A., & Galván‐Arzate, S. (2001) · Neuroreport · doi:10.1097/00001756-200108280-00020 · Cited by 106

Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis

Guillemin, G. J., Meininger, V., & Brew, B. J. (2005) · Neurodegenerative Diseases · doi:10.1159/000089622 · Cited by 105 · cited 2×

Somatic and germline mosaicism in sporadic early-onset Alzheimer's disease

Beck, J. A. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh134 · Cited by 102

Energetic Dysfunction in Quinolinic Acid‐Lesioned Rat Striatum

Bordelon, Y. M., Chesselet, M., Nelson, D. R., et al. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69041629.x · Cited by 101

NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases

Nalls, M. A., Brás, J., Hernandez, D. G., Keller, M. F., Majounie, E., Renton, A. E., Saad, M., Jansen, I. E., Guerreiro, R. J., Lubbe, S. J., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.07.028 · Cited by 100

Quinolinic acid — Iron(II) complexes: Slow autoxidation, but enhanced hydroxyl radical production in the Fenton reaction

Plátenı́k, J., Stopka, P., Vejražka, M., & Štípek, S. (2001) · Free Radical Research · doi:10.1080/10715760100300391 · Cited by 100

The Involvement of Neuroinflammation and Kynurenine Pathway in Parkinson's Disease

Zinger, A., Barcia, C., Herrero, M. T., & Guillemin, G. J. (2011) · Parkinson s Disease · doi:10.4061/2011/716859 · Cited by 99

Kynurenines, Parkinson’s disease and other neurodegenerative disorders: preclinical and clinical studies

Németh, H., Toldi, J., & Vécsei, L. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_45 · Cited by 99

Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease

Hartai, Z., Klivènyi, P., Janáky, T., Penke, B., László, A., & Vécsei, L. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.07.006 · Cited by 98

Astrocytes: New Targets for the Treatment of Neurodegenerative Diseases

Finsterwald, C., Magistretti, P. J., & Lengacher, S. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150710144502 · Cited by 98

Modeling dyskinesia in animal models of Parkinson disease

Morin, N., Jourdain, V. A., & Paolo, T. D. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.01.024 · Cited by 97

The effect of quinolinate on rat brain lipid peroxidation is dependent on iron

Štípek, S., Šťastný, F., Plátenı́k, J., Crkovska, J., & Zima, T. (1997) · Neurochemistry International · doi:10.1016/s0197-0186(97)90002-4 · Cited by 97

Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects

Muller, N., Myint, A.-M., & J. Schwarz, M. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795049552 · Cited by 94 · cited 1×

Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment

Calon, F., Morissette, M., Ghribi, O., Goulet, M., Grondin, R., Blanchet, P. J., Bédard, P. J., & Paolo, T. D. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00237-8 · Cited by 93

Rotenone induces neuronal death by microglial phagocytosis of neurons

Emmrich, J., Hornik, T. C., Neher, J. J., & Brown, G. C. (2013) · FEBS Journal · doi:10.1111/febs.12401 · Cited by 93

Neurodegeneration in Parkinson's Disease: Interactions of Oxidative Stress, Tryptophan Catabolites and Depression with Mitochondria and Sirtuins

Anderson, G., & Maes, M. H. J. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8554-z · Cited by 92

Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum

Herrero, M. T., Lévy, R., Ruberg, M., Luquín, M. R., Villares, J., López-Guillén, J. L., Faucheux, B. A., Javoy-Agid, F., Guridi, J., Agid, Y., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.219 · Cited by 92

Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys

Grégoire, L., Rassoulpour, A., GUIDETTI, P., Samadi, P., BEDARD, P., Izzo, E., Schwarcz, R. M., & Paolo, T. D. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.08.007 · Cited by 91

Uncoupling protein 2 deficiency aggravates astrocytic endoplasmic reticulum stress and nod-like receptor protein 3 inflammasome activation

Lu, M., Sun, X., Qiao, C., Liu, Y., Ding, J., & Hu, G. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.015 · Cited by 91

Rotenone Directly Induces BV2 Cell Activation via the p38 MAPK Pathway

Gao, F., Chen, D., Hu, Q., & Wang, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072046 · Cited by 91

Antioxidant treatment protects striatal neurons against excitotoxic insults

Nakao, N., Grasbon-Frodl, E. M., Widner, H., & Brundin, P. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00034-6 · Cited by 90

Protection of MPTP-induced neuroinflammation and neurodegeneration by Pycnogenol

Khan, M. M., Kempuraj, D., Thangavel, R., & Zaheer, A. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.01.029 · Cited by 88

The kynurenate analog SZR-72 prevents the nitroglycerol-induced increase of c-fos immunoreactivity in the rat caudal trigeminal nucleus: Comparative studies of the effects of SZR-72 and kynurenic acid

Knyihár‐Csillik, E., Mihály, A., Krisztin‐Péva, B., Robotka, H., Szatmári, I., Fülöp, F., Toldi, J., Csillik, B., & Vécsei, L. (2008) · Neuroscience Research · doi:10.1016/j.neures.2008.04.009 · Cited by 88

FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson's disease

der Perren, A. V., Macchi, F., Toelen, J., Carlon, M. S., Maris, M., de Loor, H., Kuypers, D. R. J., Gijsbers, R., den Haute, C. V., Debyser, Z., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.01.014 · Cited by 87

Cinnabarinic Acid, an Endogenous Metabolite of the Kynurenine Pathway, Activates Type 4 Metabotropic Glutamate Receptors

Fazio, F., Lionetto, L., Molinaro, G., Bertrand, H., Acher, F., Ngomba, R. T., Notartomaso, S., Curini, M., Rosati, O., Scarselli, P., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.074765 · Cited by 86

Effects of Kynurenine Pathway Metabolites on Intracellular NAD + Synthesis and Cell Death in Human Primary Astrocytes and Neurons

Braidy, N., Grant, R., Brew, B. J., Adams, S., Jayasena, T., & Guillemin, G. J. (2009) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s2318 · Cited by 85

Quinolinate-induced cortical cholinergic damage: modulation by tryptophan metabolites

Jhamandas, K. H., Boegman, R. J., Beninger, R. J., & Bialik, M. (1990) · Brain Research · doi:10.1016/0006-8993(90)90826-w · Cited by 80

Metalloproteinase-9 contributes to inflammatory glia activation and nigro-striatal pathway degeneration in both mouse and monkey models of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism

Annese, V., Herrero, M. T., Pentima, M. D., Gómez, A., Lombardi, L., Ros, C. M. B., de Pablos, V., Fernández‐Villalba, E., & Stefano, M. E. D. (2014) · Brain Structure and Function · doi:10.1007/s00429-014-0718-8 · Cited by 78

Purine metabolism gene deregulation in P arkinson's disease

Garcia‐Esparcia, P., Hernández‐Ortega, K., Ansoleaga, B., et al. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12221 · Cited by 77

Quinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies

Sundaram, G., Brew, B. J., Jones, S. P., Adams, S., Lim, C. K., & Guillemin, G. J. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0204-5 · Cited by 77

The Kynurenine Pathway in Stem Cell Biology

Jones, S. P., Guillemin, G. J., & Brew, B. J. (2013) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s12626 · Cited by 76

Protective effect of l-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: Implications of modulating kynurenate as a protective strategy

Silva‐Adaya, D., de la Cruz, V. P., Villeda‐Hernández, J., Carrillo-Mora, P. U., González-Herrera, I. G., Garcı́a, E., Colín-Barenque, L., Pedraza‐Chaverrí, J., & Santamarı́a, A. (2010) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2010.10.002 · Cited by 75

Evidence that quinolinic acid severely impairs energy metabolism through activation of NMDA receptors in striatum from developing rats

Ribeiro, C., Grando, V., Dutra, C. S., Wannmacher, C. M., & Wajner, M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04199.x · Cited by 73

Acute intrastriatal administration of quinolinic acid provokes hyperphosphorylation of cytoskeletal intermediate filament proteins in astrocytes and neurons of rats.

Pierozan, P., Zamoner, A., Soska, Â. K., Silvestrin, R., Loureiro, S., Heimfarth, L., Souza, T. M., Wajner, M., & Pessoa-Pureur, R. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.03.009 · Cited by 73

Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease

Duty, S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00882.x · Cited by 71

Evidence for More than One Parkinson's Disease-Associated Variant within the HLA Region

Hill‐Burns, E. M., Factor, S. A., Zabetian, C. P., Thomson, G. J., & Payami, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027109 · Cited by 71

Erratum: IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson’s disease

Barcia, C., Ros, C. M., Annese, V., Gómez, A. M., Ros‐Bernal, F., Aguado‐Llera, D., Martínez-Pagán, M. E., de Pablos, V., Fernández‐Villalba, E., & Herrero, M. T. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.123 · Cited by 67

Characterization of the kynurenine pathway in NSC‐34 cell line: implications for amyotrophic lateral sclerosis

Chen, Y.-Q., Brew, B. J., & Guillemin, G. J. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07159.x · Cited by 65

Proteomic profiling of the substantia nigra demonstrates CNDP2 overexpression in Parkinson's disease

Licker, V., Côte, M., Lobrinus, J. A., Rodrigo, N., Kövari, E., Hochstrasser, D. F., Turck, N., Sanchez, J., & Burkhard, P. R. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.02.032 · Cited by 65

Local Melatonin Regulates Inflammation Resolution: A Common Factor in Neurodegenerative, Psychiatric and Systemic Inflammatory Disorders

Anderson, G., & Maes, M. H. J. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140711091400 · Cited by 65

Enhanced neuronal damage by co‐administration of quinolinic acid and free radicals, and protection by adenosine A 2A receptor antagonists

Behan, W. M. H., & Stone, T. W. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704613 · Cited by 65

Kynurenine Pathway and Disease: An Overview

Santamarı́a, A., Cruz, V. L., & Königsberg, M. (2007) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152707783399229 · Cited by 64

Quinolinic Acid and Active Oxygens

Goda, K., KISHIMOTO, R., Shimizu, S., Hamane, Y., & Ueda, M. (1996) · Advances in experimental medicine and biology · doi:10.1007/978-1-4613-0381-7_38 · Cited by 64

Kynurenic acid attenuates MPP+-induced dopaminergic neuronal cell death via a Bax-mediated mitochondrial pathway

Lee, D., Lee, K., Lee, H. J., Noh, Y. H., Kim, D. H., Lee, J., Cho, S. H., Yoon, O. J., Lee, W. B., Kim, K. Y., et al. (2008) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2008.03.003 · Cited by 63

Quinolinic acid and active oxygens. Possible contribution of active Oxygens during cell death in the brain.

Goda, K., KISHIMOTO, R., Shimizu, S., Hamane, Y., & Ueda, M. (1996) · PubMed · Cited by 63

The Role of Group I and Group II Metabotropic Glutamate Receptors in Modulation of Striatal NMDA and Quinolinic Acid Toxicity

Orlando, L. R., Alsdorf, S. A., Penney, J. B., & Young, A. B. (2001) · Experimental Neurology · doi:10.1006/exnr.2000.7542 · Cited by 62

Neuroprotection with a new kynurenic acid analog in the four-vessel occlusion model of ischemia

Gellért, L., Fuzik, J., Göblös, A., Sárközi, K., Marosi, M., Kis, Z., Farkas, T., Szatmári, I., Fülöp, F., Vécsei, L., et al. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.05.069 · Cited by 62

Understanding the Roles of the Kynurenine Pathway in Multiple Sclerosis Progression

Lim, C. K., Brew, B. J., Sundaram, G., & Guillemin, G. J. (2010) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s4294 · Cited by 61

Chronic Administration of Quinolinic Acid in the Rat Striatum Causes Spatial Learning Deficits in a Radial Arm Water Maze Task

Shear, D. A., Dong, J., Haik-Creguer, K. L., Bazzett, T. J., Albin, R. L., & Dunbar, G. L. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6767 · Cited by 61

Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment

Knyihár‐Csillik, E., Csillik, B., Pákáski, M., Krisztin‐Péva, B., Dobó, E., Okuno, E., & Vécsei, L. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.04.043 · Cited by 61

1-Methyl-4-phenylpyridinium and 3-nitropropionic acid diminish cortical synthesis of kynurenic acid via interference with kynurenine aminotransferases in rats

Luchowski, P., Luchowska, E., Turski, W. A., & Urbańska, E. M. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00735-8 · Cited by 59

Involvement of mitochondrial potential and calcium buffering capacity in minocycline cytoprotective actions

Fernández-Gómez, F.-J., Galindo, M. F., Gómez-Lázaro, M., González-García, C., Ceña, V., Aguirre, N., & Jordán, J. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.03.019 · Cited by 59

5-Hydroxyanthranilic Acid, a Tryptophan Metabolite, Generates Oxidative Stress and Neuronal Death via p38 Activation in Cultured Cerebellar Granule Neurones

Smith, A. J., Smith, R. A., & Stone, T. W. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9034-0 · Cited by 58

Tryptophan metabolism and gut-brain homeostasis

Roth, W., Zadeh, K., Vekariya, R., Ge, Y., & Mohamadzadeh, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062973 · Cited by 519

The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma.

Ramirez, A. I., de Hoz, R., Salobrar-Garcia, E., Salazar, J. J., Rojas, B., Ajoy, D., López-Cuenca, I., Rojas, P., Triviño, A., & Ramírez, J. M. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00214 · Cited by 466

Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases

Lovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393

Microglia: Agents of the CNS Pro-Inflammatory Response

Rodríguez-Gómez, J. A., Kavanagh, E., Engskog-Vlachos, P., Engskog, M. K. R., Herrera, A. J., Espinosa-Oliva, A. M., Joseph, B., Hajji, N., Venero, J. L., & Burguillos, M. A. (2020) · Cells · doi:10.3390/cells9071717 · Cited by 365

Tryptophan Metabolism in Central Nervous System Diseases: Pathophysiology and Potential Therapeutic Strategies

Huang, Y., Zhao, M., Chen, X., Zhang, R., Le, A., Hong, M., Zhang, Y., Jia, L., Zang, W., Jiang, C., et al. (2023) · Aging and disease · doi:10.14336/ad.2022.0916 · Cited by 138

The role of the kynurenine pathway and quinolinic acid in adolescent major depressive disorder

Öztürk, M., Sapmaz, Ş. Y., Kandemır, H., Taneli, F., & Aydemır, Ö. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13739 · Cited by 50

Phase-and disorder-specific differences in peripheral metabolites of the kynurenine pathway in major depression, bipolar affective disorder and schizophrenia

Brum, M., Nieberler, M., Kehrwald, C., Knopf, K., Brunkhorst-Kanaan, N., Etyemez, S., Allers, K. A., Bittner, R. A., Slattery, D. A., McNeill, R. V., et al. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2023.2169348 · Cited by 16

L -kynurenine: metabolism and mechanism of neuroprotection

Robotka, H., Toldi, J., & Vécsei, L. (2008) · Future Neurology · doi:10.2217/14796708.3.2.169 · Cited by 36

Repeated LPS Injection Induces Distinct Changes in the Kynurenine Pathway in Mice

Larsson, M. K., Faka, A., Bhat, M., Imbeault, S., Goiny, M., Orhan, F., Oliveros, A., Ståhl, S., Liu, X. C., Choi, D., et al. (2016) · Neurochemical Research · doi:10.1007/s11064-016-1939-4 · Cited by 37

Hypothesis kynurenic and quinolinic acids: The main players of the kynurenine pathway and opponents in inflammatory disease

Badawy, A. A. ‐. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2018.06.021 · Cited by 64